At the time of writing, Viking Therapeutics Inc [VKTX] stock is trading at $42.68, up 0.78%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VKTX shares have gain 11.49% over the last week, with a monthly amount drifted -17.91%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, B. Riley Securities started tracking the stock with Buy rating on November 22, 2024, and set its price target to $109. On November 04, 2024, H.C. Wainwright reiterated its Buy rating and revised its price target to $102 on the stock. JP Morgan started tracking the stock assigning a Overweight rating and suggested a price target of $80 on September 11, 2024. Morgan Stanley initiated its recommendation with a Overweight and recommended $105 as its price target on June 27, 2024. Raymond James upgraded its rating to Strong Buy for this stock on May 16, 2024, and upped its price target to $116. In a note dated March 26, 2024, Oppenheimer reiterated an Outperform rating on this stock and boosted its target price from $116 to $138.
For the past year, the stock price of Viking Therapeutics Inc fluctuated between $17.23 and $99.41. Currently, Wall Street analysts expect the stock to reach $99.75 within the next 12 months. Viking Therapeutics Inc [NASDAQ: VKTX] shares were valued at $42.68 at the most recent close of the market. An investor can expect a potential return of 133.72% based on the average VKTX price forecast.
Analyzing the VKTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.29% with Operating Profit Margin at -307.27%, Pretax Profit Margin comes in at -227.41%, and Net Profit Margin reading is -227.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.13 and Total Capital is -0.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.64 points at the first support level, and at 40.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.60, and for the 2nd resistance point, it is at 44.52.
Ratios To Look Out For
It is important to note that Viking Therapeutics Inc [NASDAQ:VKTX] has a current ratio of 36.47. Further, the Quick Ratio stands at 36.47, while the Cash Ratio is 1.96.
Transactions by insiders
Recent insider trading involved MACARTNEY LAWSON, Director, that happened on Nov 08 ’24 when 2000.0 shares were sold. Director, LAWSON MACARTNEY completed a deal on Nov 08 ’24 to buy 2000.0 shares. Meanwhile, Chief Financial Officer ZANTE GREG sold 0.13 million shares on Oct 28 ’24.
